Exocrine Pancreatic Insufficiency Treatment Market Analysis

Treatment (Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT))

By 2035, pancreatic enzyme replacement therapy (PERT) segment is estimated to hold more than 89.4% exocrine pancreatic insufficiency treatment market share. The rising prevalence of chronic pancreatic diseases such as cystic fibrosis and pancreatic cancer are prime factors driving the adoption of pancreatic enzyme replacement therapies (PERT). For instance, in August 2024, Exelixis, Inc. announced that it received approval from the U.S. Food and Drug Administration for its supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX). This drug is effective for the treatment of well- or moderately differentiated pancreatic neuroendocrine tumors (pNET), and extra-pancreatic NET (epNET) in adults. Continuous improvements in the formulations of pancreatic enzymes are further enhancing PERT’s effectiveness. The development of pancreatic micro-tablets and capsules is making the therapy more efficient, leading to better patient outcomes and high demand.

Symptom (Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Others)

In exocrine pancreatic insufficiency treatment market, diarrhea segment is expected to hold more than 28% revenue share by 2035. Diarrhea is the prime symptom leading to exocrine pancreatic insufficiency issues. The World Health Organization (WHO) report reveals that diarrhea is the leading cause of malnutrition among children and around 1.7 billion cases of diarrheal disease are diagnosed each year, across the world. Pancreatic enzyme replacement therapy effectively improves digestion, especially of fats by providing exogenous enzymes, leading to mitigation of occurrence and severity of diarrhea.

Our in-depth analysis of the global exocrine pancreatic insufficiency treatment market includes the following segments: